Goldman Sachs
SNOA icon

Goldman Sachs’s Sonoma Pharmaceuticals SNOA Stock Holding History

Goldman Sachs’s Portfolio SNOA Stock Details SNOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-506
Closed -$1.82K – 5851
2023
Q4 		$1.82K Buy
+506
New +$3.23K ﹤0.01% 5558
2019
Q2 		– Sell
-132
Closed -$22K – 5330
2019
Q1 		$22K Buy
+132
New +$20K ﹤0.01% 5047
2016
Q2 		– Sell
-73
Closed -$63K – 7240
2016
Q1 		$63K Sell
73
-3
-4% -$2.79K ﹤0.01% 6312
2015
Q4 		$79K Sell
76
-74
-49% -$78.8K ﹤0.01% 6304
2015
Q3 		$175K Buy
150
+7
+5% +$8.3K ﹤0.01% 6105
2015
Q2 		$183K Buy
+143
New +$134K ﹤0.01% 6211

Other funds holding SNOA

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Goldman Sachs's SNOA Position: Q1 2024 in Review

Goldman Sachs sold out of Sonoma Pharmaceuticals (SNOA) in Q1 2024, closing a stake of 506 shares — an estimated $1.82K sold.

Goldman Sachs first reported a position in SNOA in Q2 2015 and held it in 6 quarters. The position peaked at $183K in Q2 2015. 14 funds tracked by Wall St. Rank hold SNOA as of Q1 2024.

  • Goldman Sachs reported no remaining Sonoma Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Goldman Sachs sold 506 Sonoma Pharmaceuticals shares in Q1 2024, an estimated $1.82K.
  • Goldman Sachs first reported a position in Sonoma Pharmaceuticals in Q2 2015 and held it in 6 quarters.
  • Goldman Sachs's Sonoma Pharmaceuticals position peaked at $183K in Q2 2015.
  • 14 funds tracked by Wall St. Rank held Sonoma Pharmaceuticals as of Q1 2024.

Based on Goldman Sachs's 13F filing for Q1 2024, filed 15 May 2024.